Wyeth BioPharma

Wyeth BioPharma is dedicated to the successful development and manufacturing of recombinant protein biopharmaceuticals.

Biopharmaceutical drugs are a rapidly growing segment of Wyeth's business. As a result of the success of several innovative products such as Enbrel^® (etanercept), ReFacto^® Antihemophilic Factor (recombinant), BeneFix^® Coagulation Factor IX (recombinant), and Xyntha^® Antihemophilic Factor (Recombinant), Plasma/Albumin-Free, Wyeth is positioned at the forefront of the biopharmaceutical revolution that is transforming disease treatment around the world.

The integration of process development and manufacturing technologies is essential to maintaining leadership in the biopharmaceutical industry. Our primary objectives are:

• To continue to effectively integrate development, manufacturing, quality assurance and regulatory affairs, and create a center of excellence for recombinant, protein-based development and manufacturing
• To focus on biopharmaceutical activities such as integrated planning and decision-making, yield management, product innovation and speed to market
• To utilize process development in a pivotal role in supply management in order to increase productivity

Wyeth BioPharma brings together the state-of-the-art biopharmaceutical science, technology and production expertise that can produce recombinant protein biopharmaceuticals. The organization is built upon a foundation of people, facilities, technologies and products that have contributed to the integrated organization. With expansion in the United States and Ireland, Wyeth BioPharma is positioned to propel Wyeth's exciting biopharmaceutical pipeline and portfolio to industry leadership.

To establish itself as a major player in the industry, Wyeth BioPharma is drawing on the total corporate strength of Wyeth and leveraging its own substantial pioneering spirit, unique skills and biopharmaceutical expertise.

The vision of Wyeth BioPharma is clear — to integrate innovative development with unparalleled excellence in manufacturing, quality and commercialization, and thereby deliver first-in-class biopharmaceutical products that meet global clinical and market demand.

The culture of the organization encourages open, honest communication, creative thinking, problem-solving and diverse perspectives. This leads to working in a can-do atmosphere, in highly productive teams formed from all segments of the organization. Trust, mutual respect and the development and manufacturing of innovative, life-enhancing products drive the people within the organization.

250503-01